Lenox Wealth Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Lenox Wealth Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-24	Closed	–	–	875
2021 Q4	$0	Buy	+24	New	+$528	﹤0.01%	983

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lenox Wealth Advisors's IOVA Position: Q1 2022 in Review

Lenox Wealth Advisors sold out of Iovance Biotherapeutics (IOVA) in Q1 2022, closing a stake of 24 shares.

Lenox Wealth Advisors first reported a position in IOVA in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 249 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

Lenox Wealth Advisors reported no remaining Iovance Biotherapeutics position as of Q1 2022 after selling out during the quarter.
Lenox Wealth Advisors sold 24 Iovance Biotherapeutics shares in Q1 2022.
Lenox Wealth Advisors first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 1 quarter.
Lenox Wealth Advisors's Iovance Biotherapeutics position peaked at $0 in Q4 2021.
249 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.